Skip to content
All research profiles

Anti-inflammatory

KPV

Prepared by the ezGLP team. Sources last checked .

Also known as Lys-Pro-Val, alpha-MSH (11-13)

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

KPV is listed in the ezGLP knowledgebase under Anti-inflammatory. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category
Anti-inflammatory
Routes represented
Subcutaneous (SubQ)
Storage context
Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Published literature

No validated PubMed or DOI link is currently curated for this entry.

Safety evidence

Serious or important: potential immunogenicity, aggregation, impurity, or product-quality risks.

A dependable route-specific human interaction and side-effect profile is not established; this is not evidence of no risk.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.